Probiotic Acne Randomized Trial: What the Evidence Says

Quick Answer

Probiotic Acne Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 randomized trial, 1 preclinical study.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Studies have demonstrated that individuals with acne may exhibit a less diverse gut microbiota, characterised by reduced abundance of beneficial genera such asand, which are commonly found in healthy individuals. [Lestari Keri (2026); evidence level 2]
• Its dysregulation can exacerbate inflammation, impair immune tolerance, and promote the overgrowth of pathogenic microorganisms, mechanisms that are increasingly associated with persistent or treatment-resistant acne. [Burckhardt-Bravo Valentina (2026); evidence level 4]
• Table 1 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Comparative overview of key studies included in this narrative review.,,,,,,,,,,,,,,,,,,,,,, Table 1 Authors / Year Therapy Study Design Patients Objective Intervention Key Findings Safety Conclusion Lebeer et al. [Burckhardt-Bravo Valentina (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For probiotic acne randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Lestari Keri (2026). Oral probiotics and topical secretome to enhance clinical outcomes and microbiome restoration in acne vulgaris: a double-blind, randomised controlled trial protocol. DOI: 10.1136/bmjopen-2025-109586. PMCID: PMC13239365. PMID: 42242743. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13239365/
• Burckhardt-Bravo Valentina (2026). Update on novel acne treatments: a narrative review focused on microbiome modulation and non-pharmacological approaches ☆. DOI: 10.1016/j.abd.2025.501249. PMCID: PMC12830251. PMID: 41544313. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12830251/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.